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categorized regarding the speciﬁcs of the type of data requested.
Using a comparative framework to examine the recommenda-
tions of CDR and NICE, we describe the frequency of the dif-
ferent types of data recommended for collection post-launch to
highlight trends across jurisdictions RESULTS: Thirty-four of 64
CDR submissions recommended ‘no listing’, 17 ‘list with crite-
ria’, and 13 ‘list or list in similar manner as other drugs in the
same category’. Of the 64 appraisals, 41 were recommended to
conduct further research to either collect speciﬁc items of data
(n = 28), conduct subgroup analysis (n = 13), or collect data
using a more appropriate study design (n = 19). The most com-
monly requested item was long-term adverse events or safety
data (16/28), and this observation is consistent with the fact that,
to date, most post-launch studies are safety surveillance studies.
In addition 11 of 28 recommended the collection of clinically
important outcomes, long-term effectiveness (7/28). Similarly, 41
of 48 NICE appraisals recommended further research to collect
real-world data, including treatment pathways, effectiveness, and
long-term effectiveness or adverse events. CONCLUSION: This
review suggests that recommendations for post-launch research
from CDR and NICE appear to be similar. This highlights the
inherent weakness of regulatory trials as a piece of evidence in
informing reimbursement decisions.
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OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer
acetate (GA) compared to natalizumab (NZ) in patients diag-
nosed with relapsing-remitting multiple sclerosis (RRMS) in
the presence of long-term clinical evidence. METHODS: A
literature-based Markov model was developed with patients
transitioning through health-states based on Kurtzke expanded
disability status scale (EDSS). Patients in the model are21 years
of age with RRMS and start in any of the health-states at diag-
nosis. Patients with an EDSS score below 6.0 receive treatment.
Treatment effects for relapse and disease progression were
obtained from clinical trials and long-term clinical evidence
where available. Transition rates were estimated by applying a
percent reduction of treatment effects of therapies to natural
history rates of relapse and disease progression. Rates were
adjusted for treatment discontinuation and persistent NZ anti-
bodies. Patients incurred drug, other medical and lost worker
productivity costs. Patients on NZ incurred additional costs for
monitoring, diagnosis, and treatment of progressive multifocal
leukoencephalopathy (PML), a possible serious adverse event for
patients on NZ. Utility weights for each health-state were taken
from published utility assessments for people with RRMS. The
primary outcomes of the model were lifetime costs and quality-
adjusted life years (QALYs). Costs (2005US$) and outcomes
were discounted at 3% annually. RESULTS: The lifetime costs
per patient for GA were $430,242 and for NZ were $498,728.
QALYs during the lifetime of a patient on GA were 9.303 and
9.300 for a patient on NZ. The incremental cost per QALY for
patients on GA and NZ compared to symptomatic treatment
alone was $208,879 and $525,463 respectively. GA is cost-
saving when compared to NZ. PML had very little impact on
results. CONCLUSIONS: While incorporating all the long-term
clinical evidence, model results indicated that GA was both less
costly and more effective over a patient’s lifetime than NZ in
treating RRMS.
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OBJECTIVES: Public health care system in Paraguay is highly
centralized, compared to other Latin American sectors, and more
than half of the population relies on it in order to receive formal
treatment. The National Immunization Program (EPI) is not an
exemption, affecting the way local/departmental resources in
immunization are allocated, impacting on the effectiveness of
these investments. In addition, differences in population charac-
teristics among departments, in terms of health care behavior,
income and education, and the use of formal medicine patterns
by original ethnic groups might affect EPIxs effectiveness. The
goal of the paper is to identify how supply side characteristics
(ﬁnancial, managerial and immunization strategies) and demand
side factors impact on immunization coverage. METHODS: The
document proposes a sequential model, where local health
authorities intent to ﬁll the gap in immunization ﬁnancing and
managerial needs, based on the resources allocation and coverage
strategy deﬁned by the national health ministry, that leads the
Paraguayan immunization design. As a result, a logistic model
was implemented, where the likelihood of being vaccinated is
tested as a dependent variable, where geographical, educational
and ethnical barriers are checked. In addition, supply variables
related to ﬁnancing, coverage strategies and communicational
efforts are included. The study analyze data from the Integrated
National Household Survey (2001), complemented with a series
of immunization effectiveness indexes constructed based on man-
agement, ﬁnancing and vaccine provision criterion, distinguish-
ing among ﬁnancial sustainability, management effectiveness and
antigen supply volatility, collected from ofﬁcial sources and inter-
views with key personnel by region. RESULTS: Health care
policy variables were statistically signiﬁcant, showing the rel-
evance of social communication, measured in terms of physical,
monetary and human resources involved. CONCLUSION: The
paper shows the importance of socio-economic-cultural barriers
on the probability of being immunized, based on health behavior,
presence of formal health insurance, and main source of care
(hospital, traditional medicine, etc.).
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OBJECTIVES: To assess the generic cost-effectiveness of health
care. METHODS: We estimated the contribution of prevention
and medical care towards population health for infectious dis-
eases, cancers, and cardiovascular diseases. This contribution
was deﬁned as the difference between the current burden of
disease (BoD) and its counterfactual: a ‘null’ situation without
selected prevention (vaccinations, screening, and preventive
medication) and medical care, and accounting for the role of
other health determinants such as improvements in housing and
nutrition, and reduced smoking. The counterfactual was back-
calculated with use of historical data on incidence, survival,
mortality, and the prevalence of risk factors. The Global Burden
of Disease methodology was applied, combining incidence,
prevalence, mortality, and disability weights into multi-state
lifetables. If required, epidemiological estimates were made
internally consistent with advanced modelling techniques
(DISMOD2). The difference between the current BoD and the
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